Beone Medicines 百济神州
One significant filing since 30 May 2026, on change of interest (2 Jun 2026): 百济神州有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告.
自 30 May 2026 起有一份重大公告（change of interest，2 Jun 2026）：百济神州有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 浦银国际证券 | 季昶阳 | Buy 买入 | 11 Aug 2026 | 2 | 361.40 |
| 中邮证券 | 盛丽华,陈灿 | Buy 买入 | 7 Aug 2026 | 4 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 6 Aug 2026 | 3 | — |
| 西南证券 | 杜向阳 | Unrated | 8 Jun 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 2 of 10 reports. 每行为该券商近十二个月的最新研报；10 份中 2 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。